Literature DB >> 11788648

Cardiac involvement in thyroid hormone resistance.

George J Kahaly1, Clare H Matthews, Susanne Mohr-Kahaly, Chris A Richards, V Krishna K Chatterjee.   

Abstract

To analyze the cardiovascular alterations thought to occur in resistance to thyroid hormone (RTH), cardiac involvement in 54 patients with RTH was investigated with the help of two-dimensional and Doppler echocardiography. Data from 41 of 54 adult subjects with RTH were also compared with those of 24 and 20 cases with hyperthyroidism (H) and hypothyroidism (h), respectively, as well as 22 healthy euthyroid controls (C). With respect to the type of mutations, no correlation was found between cardiovascular features and genotype. Compared with affected adults, children with RTH showed markedly higher serum free T3 (FT3), free T4 (FT4), and baseline TSH concentrations. Compared with healthy children of comparable age, RTH children had significantly higher heart rate and lower left ventricular (LV) ejection fraction (P = 0.006). Also, higher heart rate and FT4 as well as shorter diastolic relaxation of the myocardium (all P = 0.001) between RTH subjects with and without thyrotoxic cardiovascular features were found. Cardiac symptoms (palpitations, 32% vs. 71%) and signs (sinus tachycardia, 26% vs. 79%; atrial fibrillation, 6% vs. 17%) were significantly less frequent in RTH vs. H (all P = 0.001). Compared with C and h, heart rate, cardiac output, stroke volume, and systolic aortic flow velocity were strongly increased in RTH (all P = 0.0001) and H, although ejection (P = 0.0012) and shortening (P = 0.0001) fractions of the LV were markedly lower in RTH vs. H. Diastolic parameters, such as isovolumic relaxation (P = 0.0001) and deceleration time (P = 0.013), were shorter in RTH vs. h and C. In RTH, positive correlations between FT3 and heart rate, and between FT4 and LV ejection fraction were observed, whereas negative correlations between both FT3 and FT4 and isovolumic relaxation were noted. In conclusion, these findings indicate a modulated hyperthyroid effect on cardiac systolic and diastolic function of the myocardium in RTH, whereas other parameters, such as ejection and shortening fractions of the LV, systolic diameter, and LV wall thickness, were comparable to C. Differences in term of cardiovascular changes were smaller between the RTH and C groups than the RTH and the H or h groups. Thus, an incomplete cardiac response to thyroid hormone is present in RTH.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11788648     DOI: 10.1210/jcem.87.1.8170

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Characteristics of patients with late manifestation of resistance thyroid hormone syndrome: a single-center experience.

Authors:  Rulai Han; Lei Ye; Xiaohua Jiang; Xiaoyi Zhou; Cyrielle Billon; Wenyue Guan; Karine Gauthier; Weiyuan Fang; Weiqing Wang; Jacques Samarut; Guang Ning
Journal:  Endocrine       Date:  2015-06-04       Impact factor: 3.633

2.  Resistance to thyroid hormone is associated with raised energy expenditure, muscle mitochondrial uncoupling, and hyperphagia.

Authors:  Catherine S Mitchell; David B Savage; Sylvie Dufour; Nadia Schoenmakers; Peter Murgatroyd; Douglas Befroy; David Halsall; Samantha Northcott; Philippa Raymond-Barker; Suzanne Curran; Elana Henning; Julia Keogh; Penny Owen; John Lazarus; Douglas L Rothman; I Sadaf Farooqi; Gerald I Shulman; Krishna Chatterjee; Kitt Falk Petersen
Journal:  J Clin Invest       Date:  2010-03-08       Impact factor: 14.808

3.  Thyroid hormone receptor beta gene mutation (P453A) in a family producing resistance to thyroid hormone.

Authors:  T Bayraktaroglu; J Noel; F Alagol; N Colak; N M Mukaddes; S Refetoff
Journal:  Exp Clin Endocrinol Diabetes       Date:  2008-06-17       Impact factor: 2.949

4.  [A 46-year-old patient with atrial fibrillation, elevated thyroid hormones and normal thyrotropine].

Authors:  I V Opherk; B Gutt; S Volz; T Siegmund; P M Schumm-Draeger
Journal:  Internist (Berl)       Date:  2010-03       Impact factor: 0.743

5.  Thyroid hormone levels within reference range are associated with heart rate, cardiac structure, and function in middle-aged men and women.

Authors:  Greet L Roef; Youri E Taes; Jean-Marc Kaufman; Caroline M Van Daele; Marc L De Buyzere; Thierry C Gillebert; Ernst R Rietzschel
Journal:  Thyroid       Date:  2013-07-17       Impact factor: 6.568

6.  Syndrome of Reduced Sensitivity to Thyroid Hormones: Two Case Reports and a Literature Review.

Authors:  Anastasios Anyfantakis; Dimitrios Anyfantakis; Irene Vourliotaki
Journal:  Case Rep Endocrinol       Date:  2016-09-28

7.  Resistance to Thyroid Hormone Complicated with Type 2 Diabetes and Cardiomyopathy in a Patient with a TRβ Mutation.

Authors:  Hisao Wakasaki; Miyuki Matsumoto; Shinya Tamaki; Kaori Miyata; Shohei Yamamoto; Takamasa Minaga; Yoshitaka Hayashi; Kenichi Komukai; Toshio Imanishi; Hiroyuki Yamaoka; Shohei Matsuno; Masahiro Nishi; Takashi Akamizu
Journal:  Intern Med       Date:  2016-11-15       Impact factor: 1.271

8.  Homozygous Resistance to Thyroid Hormone β: Can Combined Antithyroid Drug and Triiodothyroacetic Acid Treatment Prevent Cardiac Failure?

Authors:  Carla Moran; Abdelhadi M Habeb; George J Kahaly; Christoph Kampmann; Marina Hughes; Jan Marek; Odelia Rajanayagam; Adam Kuczynski; Faraneh Vargha-Khadem; Mofeed Morsy; Amaka C Offiah; Ken Poole; Kate Ward; Greta Lyons; David Halsall; Lol Berman; Laura Watson; David Baguley; John Mollon; Anthony T Moore; Graham E Holder; Mehul Dattani; Krishna Chatterjee
Journal:  J Endocr Soc       Date:  2017-08-08

9.  Thyroid Hormone Resistance in Identical Twin Sisters with Atrial Fibrillation: Case Report and Review of the Literature.

Authors:  Mark B Zimering
Journal:  J Endocrinol Diabetes       Date:  2018-07-23

10.  Multi-tissue gene-expression analysis in a mouse model of thyroid hormone resistance.

Authors:  Lance D Miller; Peter McPhie; Hideyo Suzuki; Yasuhito Kato; Edison T Liu; Sheue-yann Cheng
Journal:  Genome Biol       Date:  2004-04-29       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.